BSH 2017 | How the treatment of AML will change
Mary F. McMullin
Mary Frances McMullin, MD of Belfast City Hospital, Belfast, UK discusses targeted therapy and immunotherapy for acute myeloid leukemia (AML) held at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. Prof. McMullin explains that she was part of a discussion at BSH on targeted therapy and immunotherapy for AML. We are in the era of molecular medicine as our understanding of mutations underlying disease is improving and she explains that this may change the treatment of AML.
Related videos
An exciting era for CAR T-cell therapy
Mohamad Mohty
0:56 Harmonizing MRD reporting criteria
Christopher Hourigan
1:25 MRD testing will be a part of future AML clinical trials
Christopher Hourigan
2:15 Improving the specificity of molecular MRD detection
Christopher Hourigan
2:11 Targeted RNA-sequencing for the quantification of MRD in AML
Christopher Hourigan
